Ovid Therapeutics Inc. (NASDAQ: OVID) had its "outperform" rating re-affirmed by analysts at Wedbush.
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire
- Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of DirectorsGlobeNewswire
- Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswire
OVID
Earnings
- 3/11/25 - Beat
OVID
Sec Filings
- 3/11/25 - Form 10-K
- 3/11/25 - Form 8-K
- 3/5/25 - Form 8-K
- OVID's page on the SEC website